Venkata S K Manem
Overview
Explore the profile of Venkata S K Manem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
208
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang Y, Manem V
Front Oncol
. 2025 Mar;
15:1492758.
PMID: 40071099
Purpose: In the context of lung cancer screening, the scarcity of well-labeled medical images poses a significant challenge to implement supervised learning-based deep learning methods. While data augmentation is an...
2.
Al Dow M, Secco B, Mouchiroud M, Rochette M, Gilio G, Massicard M, et al.
Obesity (Silver Spring)
. 2025 Feb;
33(3):522-536.
PMID: 39956640
Objective: Adipose tissue expands through hyperplasia and hypertrophy to store excess lipids, a process that is essential for the maintenance of metabolic homeostasis. The mechanisms regulating adipocyte recruitment from progenitors...
3.
Ebrahimpour L, Despres P, Manem V
Cancer Med
. 2024 Oct;
13(20):e70359.
PMID: 39463128
Objective: Lung cancer remains the leading cause of cancer-related mortality worldwide, with most cases diagnosed at advanced stages. Hence, there is a need to develop effective predictive models for early...
4.
Boullier C, Lamaze F, Haince J, Bux R, Orain M, Zheng J, et al.
Cancers (Basel)
. 2024 Sep;
16(18).
PMID: 39335151
Background/objectives: Pulmonary neuroendocrine neoplasms (NENs) account for 20% of malignant lung tumors. Their management is challenging due to their diverse clinical features and aggressive nature. Currently, metabolomics offers a range...
5.
Ebrahimpour L, Lemarechal Y, Yolchuyeva S, Orain M, Lamaze F, Driussi A, et al.
Br J Radiol
. 2024 Sep;
97(1164):1982-1991.
PMID: 39287013
Objectives: Radiomics can predict patient outcomes by automatically extracting a large number of features from medical images. This study is aimed to investigate the sensitivity of radiomics features extracted from...
6.
Vahidian F, Lamaze F, Bouffard C, Coulombe F, Gagne A, Blais F, et al.
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398098
Immune checkpoint inhibitors (ICIs) have revolutionized non-small cell lung cancers (NSCLCs) treatment, but only 20-30% of patients benefit from these treatments. Currently, PD-L1 expression in tumor cells is the only...
7.
Dia A, Ebrahimpour L, Yolchuyeva S, Tonneau M, Lamaze F, Orain M, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254838
Background: Recent advances in cancer biomarker development have led to a surge of distinct data modalities, such as medical imaging and histopathology. To develop predictive immunotherapy biomarkers, these modalities are...
8.
Kolnohuz A, Ebrahimpour L, Yolchuyeva S, Manem V
BMC Cancer
. 2024 Jan;
24(1):2.
PMID: 38166789
Background: Although substantial efforts have been made to build molecular biomarkers to predict radiation sensitivity, the ability to accurately stratify the patients is still limited. In this study, we aim...
9.
Yolchuyeva S, Giacomazzi E, Tonneau M, Lamaze F, Orain M, Coulombe F, et al.
JTO Clin Res Rep
. 2023 Dec;
4(12):100602.
PMID: 38124790
Background: Although the immune checkpoint inhibitors, nivolumab and pembrolizumab, were found to be promising in patients with advanced NSCLC, some of them either do not respond or have recurrence after...
10.
Yolchuyeva S, Giacomazzi E, Tonneau M, Ebrahimpour L, Lamaze F, Orain M, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568646
Background: Immune checkpoint inhibitors (ICIs) are a great breakthrough in cancer treatments and provide improved long-term survival in a subset of non-small cell lung cancer (NSCLC) patients. However, prognostic and...